A Phase I Dose Escalation Study of MK0457 [VX 680, tozasertib] Evaluating the Safety Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer

Trial Profile

A Phase I Dose Escalation Study of MK0457 [VX 680, tozasertib] Evaluating the Safety Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs Tozasertib (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 15 Jan 2008 The expected completion date for this trial is now 1 Nov 2007.
    • 22 Dec 2007 Patient numbers, completion date and official title changed as per ClinicalTrials.gov.
    • 19 Nov 2007 Status change from recruiting to terminated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top